Puro Pharmaceuticals: Overall orders remained relatively stable in the second half of the year.

On July 15th, Proro Pharmaceutical Industry stated on the interactive platform that the company's overall orders in the second half of the year remained relatively stable. Among them, CDMO orders grew rapidly, API business was in the ramp-up period of new projects and new production capacity, and the formulation business was also in the rapid increase phase of ANDA.